Zenlabs Ethica Limited markets and distributes pharmaceutical products primarily in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The company is also involved in the private label manufacturing of various pharmaceutical products, such as tablets, capsules, injections, syrups, and ointments; and therapeutics, such as anti-infective, anti-obesity, anti-bacterial, anti-hypertensives, anti-fungal, pain killers, and nutritional supplements. It serves customers through a network of distributors and stockists in Myanmar, Indonesia, Malaysia, Thailand, Cambodia, Vietnam, Laos, the Philippines, S
| Current Price | ₹32.91 |
|---|---|
| Market Cap | ₹22 Cr |
| Sector | Health Care > Health Care Equipment and Services > Health Care Providers and Services |
| Sub-Industry | Health Care Distributors > Pharmaceutical Product Distribution |
| P/E Ratio | -11.2 |
| Return on Equity | -20.44% |
| 52-Week Range | ₹16.50 – ₹39.99 |
| Beta (1Y) | 0.9 |
| Dividend Yield | 0.00% |
1. Pharmaceuticals Formulation-100%
Zenlabs Ethica Ltd is trading at ₹32.91, with a market capitalisation of ₹22 Cr.
Zenlabs Ethica Ltd operates in the Health Care > Health Care Equipment and Services > Health Care Providers and Services space (Health Care Distributors > Pharmaceutical Product Distribution).
Zenlabs Ethica Ltd has a P/E of -11.2 and a return on equity of -20.44%.